Update on £30m Sir Bobby Robson Institute for cancer research and care at Newcastle’s Freeman Hospital

A £30 million centre for pioneering cancer research and treatment will be built at Newcastle’s Freeman Hospital.

City leaders have approved plans for the new Sir Bobby Robson Institute, which it is hoped will become a world-leading facility for groundbreaking innovations in cancer treatment that could help people around the globe.

The centre will bring together the existing Sir Bobby Robson Cancer Trials Research Centre, which was opened by the former Newcastle United manager just months before his death in 2009, and the Freeman’s cancer and blood disorders research team.

Construction will start early next year on the purpose-built trials facility, which was granted permission by Newcastle City Council’s planning committee on Friday and should be open in 2028. 

Supporters of the Sir Bobby Robson Foundation, part of Newcastle Hospitals Charity, have already raised £20 million for the development and a fundraising campaign is being launched to secure the final £10 million needed.

Councillors heard on Friday morning how the foundation’s existing centre had produced enormous benefit” in the evolution of cancer treatment, but had outgrown its current space and been forced to reject some research programmes due to a lack of capacity.

Relocating to a “flagship” standalone building within the grounds of the Freeman Hospital site will provide a bespoke unit for cancer trials that can include more patients and more complex research.

placeholder image
LDRS

Teri Bayliss, director at Newcastle Hospitals Charity, said: “This project will be the proud culmination of a phenomenal fundraising effort and, alongside the many cancer patients who will benefit from the scientific advances made by the trials team, we are extremely grateful to all those who are supporting the project.

“We are particularly indebted to those organisations and individuals who have shown leadership support for our fundraising campaign, including the Sir James Knott Trust and Esh Group.

“We hope that others will join our continued efforts early in the new year when we have a match funding challenge for the next £1m raised. This project and the leadership behind it is inspired by Sir Bobby’s dream for people in our region to have access to world-class cancer treatment.”

Sir Bobby, who battled cancer five times during his life, launched his foundation in 2008 with the initial aim to raise £500,000 to equip a new cancer drug trials centre at the Northern Centre for Cancer Care.

Hospital bosses say that the new institute, which will also be named after the beloved former NUFC and England boss, will provide “much-needed additional capacity” to increase the number of cancer clinical trials taking place in Newcastle by 50% over five years.

The three-storey facility will be built on a patch of land in the north-east corner of the Freeman Hospital site, next to the Coxlodge Wagonway, which currently houses a small car park. 

placeholder image
LDRS

Professor Ruth Plummer, consultant medical oncologist at Newcastle Hospitals and director of the Sir Bobby Robson Cancer Trials Research Centre, said: “Demand for more research into new and innovative cancer treatments is rising, globally and locally. At Newcastle Hospitals we have skilled and experienced teams who are already carrying out ground-breaking cancer clinical trials.

“Over the years, we have become increasingly busy and current limitations mean our space to conduct more trials is restricted so, frustratingly, the team cannot accept some research programmes or requests. I’m absolutely thrilled that we’ve been given permission to build this new facility, which will allow us to provide timely access to clinical trials for many more eligible cancer patients, including those who have exhausted current treatments.

“More research trials will inevitably lead to better health outcomes and improve the treatment we are able to provide for cancer patients both now and in the future.”

Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice